Eli Lilly has announced the launch of its registered diabetic injection Byetta
(exenatide injection) in India.
The drug treats patients with Type2 diabetes,
as part of the prescription with two common oral diabetes medications, metformin
and / or sulphonylureas.
is the first in a new class of anti-diabetic medicines known as incretin mimetics
and is the first FDA-approved agent of this category, a company statement quoted
Sandeep Gupta, CMD, Lilly India, as saying. The statement hails Byetta as a novel
approach to treating type 2 diabetes.